Tag: Roche
Next Generation Immunotherapies
The immune system has already provided a number of potent strategies for treating cancers that are already impacting clinic, which in turn has stimulated...
Eric Rosenthal Reports: Why Academia Wasn’t Ready to Build Big Data...
Big news hit the pharmaceutical industry in February when Roche Pharmaceuticals announced that it would be acquiring big-data firm Flatiron Health for $1.9 billion.
Roche...
Antibody-drug Conjugates: Technologies and Global Markets
Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new. Due to many technological advances, recognition of appropriate target antigens, success...
Improving Outcomes in the Treatment of Breast Cancer (Video)
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of these promising new therapeutic agents...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
Roche and Catalent Start Research Collaboration on SMARTAG™ Technology
New Jersey based Catalent has agreed to a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using the company's proprietary SMARTag™...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial
Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...
Heidelberg Pharma and Roche Discontinue Collaboration
Roche is discontinuing its partnership with the Wilex subsidiary Heidelberg Pharma for the development of antibody-targeted amanitin conjugates or ATACs. The licence agreement was signed...
ADC Market to Reach US$ 3 Billion by 2018
According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...
